Login to Your Account



Sygnis Shares Plunge on AX200 Acute Ischemic Stroke Miss

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, December 21, 2011
Shares in Sygnis Pharma AG plunged more than 62 percent Friday on news that its lead drug AX200 failed to demonstrate efficacy in a 328-patient Phase IIb trial in acute ischemic stroke.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription